Loading clinical trials...

Cabozantinib and Pembrolizumab in Metastatic Pancreas | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Phase II Clinical Trial Evaluating Cabozantinib and Pembrolizumab in Metastatic Pancreatic Cancer

NCT05052723•Joseph Kim

View on ClinicalTrials.gov

Summary

This study aims to evaluate cabozantinib and pembrolizumab for the treatment of metastatic pancreatic adenocarcinoma.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Diagnosis of pancreatic ductal adenocarcinoma
•Evidence of progression or intolerance to previous standard of care pancreatic cancer systemic or locoregional therapies
•Patients must have adequate organ function

Exclusion Criteria

•Chemotherapy or other locoregional anti-tumoral therapies performed within 28 days of study treatment initiation
•Received palliative radiation therapy within 2 weeks or any other radiation therapy within 4 weeks of start of study intervention
•Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to allocation
•Has a diagnosis of immunodeficiency (autoimmune disease) or is receiving chronic systemic steroid therapy
•Clinically significant cardiovascular disease
•Uncontrolled hypertension
•Inability to swallow tablets

Locations (1)

University of Kentucky Markey Cancer Center

Lexington, Kentucky, United States

Key Dates

Start Date

January 4, 2022

Primary Completion Date

November 5, 2024

Completion Date

November 5, 2024

Last Updated

November 19, 2025

Enrollment

ACTUAL participants

Conditions

Pancreatic Cancer

Interventions

Cabozantinib

DRUG

Pembrolizumab

DRUG

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

NCT05053971

Advanced Malignant Solid NeoplasmLocally Advanced Pancreatic Carcinoma+7 more

View study

RECRUITINGPHASE2

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

NCT04550494

Anatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+29 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 19, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Cabozantinib and Pembrolizumab in Metastatic Pancreas

Inclusion Criteria

Exclusion Criteria

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Resilience and Equity in Aging, Cancer, and Health (REACH)

A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer

PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples

Efficacy of Gembrax Followed by Folfirinox Versus Folfirinox Alone in First Metastatic Line Pancreatic Cancer Patients